Global analysis shows widespread suitability for GLP-1 drugs for weight loss.

Global analysis shows widespread suitability for GLP-1 drugs for weight loss.

Introduction to the topic of obesity and treatment options

The global prevalence of obesity has more than doubled in the last three decades. This brings with it an increase in weight-related diseases such as diabetes, cardiovascular disease and cancer. This health crisis is straining global health systems and economies. A new study co-led by researchers at Mass General Brigham may help develop strategic programs to incorporate GLP-1 drugs as part of the solution.

Results of the study

Researchers from Mass General Brigham and partners at Washington University School of Medicine in St. Louis and Emory University's Rollins School of Public Health compiled data from 99 countries and 810,635 adults. They found that more than one in four adults worldwide are eligible for the use of GLP-1 drugs for weight loss, particularly women, the elderly and those from low-income countries.

Key insights

• Über 25% der Erwachsenen könnten von GLP-1 profitieren.
• Besonders viele Betroffene kommen aus einkommensschwachen Ländern.
• Frauen und ältere Menschen haben höhere Chancen, für die Behandlung in Frage zu kommen.

Understanding GLP-1 Drugs

A researcher, Dr. Jennifer Manne-Goehler, explained that there has never been such a promising and scalable tool for obesity and related diseases. We've long been told that the problem lies in our own behavior - that we need to exercise more and eat less. But these drugs help us understand that the biological aspects are much more complex.

Global challenges and access to GLP-1

WHO has recognized the importance of GLP-1 drugs and is working to make them available worldwide. A central problem here is the question: How many people actually need these medications?

Dr. Sang Gune K. Yoo emphasizes that more than a quarter of adults worldwide could benefit from these drugs, although further research is needed to ensure their long-term safety. Access remains a major challenge as these drugs are difficult to obtain in many regions.

Study career

Researchers analyzed health data from household surveys in 99 countries between 2008 and 2021. Of the total 810,635 adults aged 25 to 64, those whose diabetes biomarkers, blood pressure and BMI values ​​were available were selected. People with a BMI over 30 or more than 27 with additional health problems were identified as potential users of GLP-1 drugs.

Global distribution of suitability for GLP-1

Overall, 27% of adults were eligible for GLP-1 treatment for weight loss, with four-fifths coming from low-income countries. The suitability rate was highest in Europe and North America (42.8%) and the Pacific Islands (41.0%).

Socio-economic aspects

• Frauen (28,5%) sind eher geeignet als Männer.
• Ältere Menschen (38,3%) sind häufiger geeignet als jüngere Personen (17,9%).

Dr. Manne-Goehler emphasizes that access opportunities for women and certain population groups are of great importance, especially in regions with high mortality from type 2 diabetes. Access to GLP-1 medicines is a health equity issue, and it is critical that these medicines not only benefit the easiest to reach people.

Sources: